In this phase II , randomized , open-label , active-controlled , multicenter clinical trial , patients were randomized 1:1 to either 1.02 g ferumoxytol ( 2 510-mg injections ) or 1.0 g iron sucrose administered as either a slow injection or infusion ( 10 doses for dialysis patients and 5 doses for nondialysis patients ) .